- Home
- SGML vs MLTX Comparison
SGML vs MLTX Comparison
Compare SGML & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGML | MLTX |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | Brazil | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SGML | MLTX |
|---|---|---|
| Price | $10.74 | $15.68 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $16.75 | ★ $22.22 |
| AVG Volume (30 Days) | ★ 5.2M | 3.6M |
| Earning Date | 11-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,959,151.00 | N/A |
| Revenue This Year | $52.45 | N/A |
| Revenue Next Year | $22.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.25 | $5.95 |
| 52 Week High | $16.87 | $62.75 |
Technical Indicators
Market Signals| Indicator | SGML | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 52.02 |
| Support Level | $11.89 | $15.62 |
| Resistance Level | $15.14 | $16.57 |
| Average True Range (ATR) | 1.61 | 0.98 |
| MACD | -0.45 | -0.08 |
| Stochastic Oscillator | 1.77 | 13.59 |
Price Performance
Historical ComparisonAbout SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.